TW202228678A - 依達拉奉經口投予用醫藥組成物及其投予方法 - Google Patents

依達拉奉經口投予用醫藥組成物及其投予方法 Download PDF

Info

Publication number
TW202228678A
TW202228678A TW110142253A TW110142253A TW202228678A TW 202228678 A TW202228678 A TW 202228678A TW 110142253 A TW110142253 A TW 110142253A TW 110142253 A TW110142253 A TW 110142253A TW 202228678 A TW202228678 A TW 202228678A
Authority
TW
Taiwan
Prior art keywords
administration
edaravone
pharmaceutical composition
hours
meal
Prior art date
Application number
TW110142253A
Other languages
English (en)
Chinese (zh)
Inventor
清水秀俊
仲丸善喜
西村祐貴子
Original Assignee
日商田邊三菱製藥股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=81602356&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TW202228678(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 日商田邊三菱製藥股份有限公司 filed Critical 日商田邊三菱製藥股份有限公司
Publication of TW202228678A publication Critical patent/TW202228678A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TW110142253A 2020-11-12 2021-11-12 依達拉奉經口投予用醫藥組成物及其投予方法 TW202228678A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2020188514 2020-11-12
JP2020-188514 2020-11-12

Publications (1)

Publication Number Publication Date
TW202228678A true TW202228678A (zh) 2022-08-01

Family

ID=81602356

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110142253A TW202228678A (zh) 2020-11-12 2021-11-12 依達拉奉經口投予用醫藥組成物及其投予方法

Country Status (11)

Country Link
US (2) US11911366B2 (cg-RX-API-DMAC7.html)
EP (1) EP4245303A4 (cg-RX-API-DMAC7.html)
JP (2) JPWO2022102737A1 (cg-RX-API-DMAC7.html)
KR (1) KR20230098267A (cg-RX-API-DMAC7.html)
CN (1) CN116761601A (cg-RX-API-DMAC7.html)
AR (1) AR124062A1 (cg-RX-API-DMAC7.html)
AU (2) AU2021380319B2 (cg-RX-API-DMAC7.html)
CA (1) CA3198014A1 (cg-RX-API-DMAC7.html)
IL (1) IL302533A (cg-RX-API-DMAC7.html)
TW (1) TW202228678A (cg-RX-API-DMAC7.html)
WO (1) WO2022102737A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024036261A2 (en) * 2022-08-10 2024-02-15 Kpr U.S., Llc Occlusion detection system and method for a flow control apparatus
EP4559463A1 (en) * 2023-11-23 2025-05-28 Ferrer Internacional, S.A. Edaravone or its salts for use in the treatment of oxidative stress-mediated neurodegenerative disorders

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61263917A (ja) 1985-05-20 1986-11-21 Mitsubishi Yuka Yakuhin Kk 脳機能正常化剤
JPH0531523A (ja) 1991-07-26 1993-02-09 Aichi Steel Works Ltd ロ−ラ回転数・間隙測定可能な圧延機用ロ−ラガイド装置
ES2248144T3 (es) 2000-10-24 2006-03-16 Mitsubishi Pharma Corporation Medicamentos para tratar la esclerosis lateral amiotrofica (ela).
CN109125261B (zh) * 2016-03-16 2021-11-30 苏州澳宗生物科技有限公司 依达拉奉剂型
EP3785703A1 (en) * 2017-01-17 2021-03-03 Treeway TW001 B.V. Treatment comprising oral or gastric administration of edaravone
CN110381923A (zh) * 2017-01-17 2019-10-25 萃微Tw001公司 包括肠内施用依达拉奉的医学治疗
BR112021008197A2 (pt) 2018-11-02 2021-08-03 Mitsubishi Tanabe Pharma Corporation suspensão de edaravone para administração oral
JP7012792B2 (ja) 2020-08-06 2022-01-28 株式会社 ディー・エヌ・エー 動画を配信するためのシステム、方法、及びプログラム
US12194025B2 (en) 2020-11-12 2025-01-14 Mitsubishi Tanabe Pharma Corporation Pharmaceutical composition for oral administration of edaravone and method of administering same

Also Published As

Publication number Publication date
US12478611B2 (en) 2025-11-25
US20220142982A1 (en) 2022-05-12
JPWO2022102737A1 (cg-RX-API-DMAC7.html) 2022-05-19
AU2021380319B2 (en) 2025-03-20
IL302533A (en) 2023-07-01
US11911366B2 (en) 2024-02-27
CN116761601A (zh) 2023-09-15
AU2025203773A1 (en) 2025-06-12
WO2022102737A1 (ja) 2022-05-19
KR20230098267A (ko) 2023-07-03
US20240173297A1 (en) 2024-05-30
AR124062A1 (es) 2023-02-08
EP4245303A4 (en) 2024-10-09
CA3198014A1 (en) 2022-05-19
EP4245303A1 (en) 2023-09-20
JP2025061070A (ja) 2025-04-10
AU2021380319A1 (en) 2023-06-22

Similar Documents

Publication Publication Date Title
EP3731870B1 (en) Liquid oral formulations for pde v inhibitors
JP2025061070A (ja) エダラボン経口投与用医薬組成物およびその投与方法
RU2668882C2 (ru) Жидкая фармацевтическая композиция
EA019881B1 (ru) Стабилизированная суспензия каризбамата для применения в педиатрии
US12458593B2 (en) Suspensions and diluents for metronidazole and baclofen
US12527769B2 (en) Pharmaceutical composition for oral administration of edaravone and method of administering same
CN114761002A (zh) 用于奥美拉唑混悬剂的组合物和试剂盒
JPWO2014061808A1 (ja) 胃ろう栄養患者用栄養組成物
JP6157928B2 (ja) 肝臓への脂肪蓄積抑制剤
EP2668851B1 (en) Liver function-improving agent
JP6856813B1 (ja) 亜鉛点滴静注用製剤
US10973886B2 (en) Use of a pharmaceutical composition containing at least one digestive enzyme in artificial feeding
US20190060266A1 (en) Pharmaceutical compositions of tiopronin and methods for preparing thereof
KR20250099117A (ko) 도파민을 포함하는 약학적 주사용액